
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
View the Applied Clinical Trials October 2025 issue in an interactive format.
Click
about 1 year ago
In With the Newabout 1 year ago
KRI Overload: When More Isn’t Betterabout 1 year ago
Applied Clinical Trials' 2025 State of the Industry Survey





